Mesoblast Provides Update on Clinical Programs of Prochymal for Crohn's Disease and Acute Graft Versus Host Disease NEW YORK and MELBOURNE, Australia, April 28, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today provided an update on its clinical programs using the...